Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

Eligibility Criteria

• 1. Be able to provide written informed consent
• 2. Have a diagnosis of PD with evidence of stable disease as determined by the investigator
• 3. Patient must have palpable penile plaque
• 4. Penile curvature deformity of \>30° to \<90°
• 5. Agree to comply with all study related tests/procedures.
• 6. Prior intralesional platelet rich plasma treatment within the past 18 months and desire secondary treatment of penile curvature
• 1. Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting, penile prosthesis.
• 2. Previous intralesional injection therapy with CCH for PD within six months. Patients with failed therapy greater than six months ago may be included.
• 3. Previous history of priapism or penile fracture
• 4. PD characterized by a ventral plaque
• 5. Severe erectile dysfunction as characterized with an IIEF score ≤ 12
• 6. Hour-glass deformity
• 7. Unwilling to participate
• 8. Medically unfit for sexual intercourse as deemed by the principal investigator
• 9. Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with autologous PRP injection therapy.
• 10. Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.